Permanent Muscle Weakness can be incapacitating1
|
|
After years of paralytic episodes, PMW may be irreversible as muscle atrophies. The less common edematous form of PMW may be reversible with treatment.1-3
|
|
Recognize the characteristics of PPP
for earlier diagnosis and management.
Learn more
|
|
|
Contact your Area Business Specialist
[First, Last - ABS@strongbridgebio.com]
to schedule a peer-to-peer discussion
with an expert.
|
|
|
References:
1. Cavel-Greant D, Lehmann-Horn F, Jurkat-Rott K. The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients. Acta Myol. 2012;31:126-133.
2. Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol. 2015;5(2):761-790.
3. Charles G, Zheng C, Lehmann-Horn F, Jurkatt-Rott K, Levitt J. Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals. J Neurol. 2013;260:2606-2613.
4. Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. 2006;129:8-17.
|
|
This message was sent by: Strongbridge Biopharma • 900 Northbrook Drive, Suite 200 • Trevose, PA 19053
|
|
This message and any attachments are for the designated recipient only and may contain privileged, proprietary, or otherwise private information. If you have received this in error, please notify the sender immediately and delete this message. Any other use of this email is prohibited.
|
|
Unsubscribe from this list.
|
|
|
www.strongbridgebio.com
|
|
© 2018 Strongbridge Biopharma plc
|
|
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
|
|
KEV-0397 07/2018
|